Peter Ottsjö | BAIO

Oliver Buchannon

Peter Ottsjö

Peter Ottsjö is a tech journalist and author of the popular science book Evigt Ung (Forever Young), CEO of LEVITY Media Group and co-host of the LEVITY Podcast, Longevity Biotech Fellowship fellow and Vitalist.

Scientists are trading blows over virtual cells

Jul 9, 2026

•

5 min read

Scientists are trading blows over virtual cells

Plus: Insilico’s AI-designed drug enters Phase III, Biohub finds psoriasis targets in skin cells, and ATHENA teaches medical AI to check its evidence.

OpenAI’s biology test is already under pressure

Jul 6, 2026

•

6 min read

OpenAI’s biology test is already under pressure

Plus: Valence models molecules in water, there's a new Virtual Cell challenge coming up, and Takeda adds Insilico to its AI drug-discovery ecosystem.

TOP 10

The Top 10 AI x bio stories in June

Jul 4, 2026

•

5 min read

The Top 10 AI x bio stories in June

Claude Science, scientific superintelligence, ultrasound through the skull, and AI-designed antibodies for cancer’s hidden mutation flags.

Peter Ottsjö

Here's everything you need to know about Claude Science

Jul 1, 2026

•

12 min read

Here's everything you need to know about Claude Science

We bring you all the news, how people reacted and the insights behind the launch.

A little-known lab just imaged the living brain through the skull - with ultrasound

Jun 29, 2026

•

10 min read

A little-known lab just imaged the living brain through the skull - with ultrasound

Plus: AI reads more from ECGs, a garage drug candidate goes viral, and BAIO’s AI × bio tools directory is live.

AI-designed antibodies advance on a “drug-discovery holy grail”

Jun 25, 2026

•

8 min read

AI-designed antibodies advance on a “drug-discovery holy grail”

Plus: Proto links biology’s AI silos, AI-CURA reads variant evidence, NVIDIA gives agents a toolbox, and GPT-5 Pro helps revisit a T-cell mystery.

What to make of the Midjourney Scanner

Jun 22, 2026

•

8 min read

What to make of the Midjourney Scanner

Plus: OpenAI revisits rare-disease genomes, Benchling adds private lab context, and AlphaFold’s co-creator heads to Anthropic.

This is what it would take to build a true virtual cell

Jun 18, 2026

•

8 min read

This is what it would take to build a true virtual cell

Plus: Tacit Labs builds long-horizon benchmarks for AI drug discovery, Radical Numerics adds a defense layer to genome AI, and Noetik predicts drug responders from pathology slides.

Biohub makes “impossible” breakthrough in imaging

Jun 15, 2026

•

8 min read

Biohub makes “impossible” breakthrough in imaging

Plus: Claude Fable goes offline, Terray gives AI-designed molecules a recipe, TITO skips frames in molecular movies, and Tamarind powers Lilly’s TuneLab expansion

Claude Fable is great at biology - if Anthropic lets you use it

Jun 11, 2026

•

6 min read

Claude Fable is great at biology - if Anthropic lets you use it

Plus: Tahoe’s shortcut around virtual cells, NewLimit’s AI discovery engine, and AstraZeneca’s Phase 3 agent.

Scientists are the new refugees in Dario Amodei's world

Jun 11, 2026

•

2 min read

Scientists are the new refugees in Dario Amodei's world

A personal note on Claude Fable, Anthropic’s biology safeguards and the coming fight over access to frontier AI.

TOP 10

10 important lessons you should learn about AI x bio in 2026

Jun 9, 2026

•

9 min read

10 important lessons you should learn about AI x bio in 2026

What 150 stories reveal about the bottlenecks, breakthroughs and next questions in the field.

Peter Ottsjö

Why Lila may raise $2B - for “scientific superintelligence”

Jun 8, 2026

•

8 min read

Why Lila may raise $2B - for “scientific superintelligence”

Plus: Pfizer adds Chai, Nature takes stock of virtual cells, Claude tries chemistry, and AI leaders call for DNA screening.

NewLimit raises $435M for aging reprogramming

Jun 3, 2026

•

6 min read

NewLimit raises $435M for aging reprogramming

Plus: an AI reads tumor genomes as a whole, Waypoint Bio moves cell therapies toward the clinic, and bio agents go back to school.

Drug delivery is broken. This group has a plan to fix that.

May 31, 2026

•

6 min read

Drug delivery is broken. This group has a plan to fix that.

Plus: OpenAI turns Rosalind toward biodefense, AI maps cancer’s immune neighborhoods, and AI scientists learn to organize themselves.

TOP 10

The TOP 10 AI x bio stories in May

May 29, 2026

•

5 min read

The TOP 10 AI x bio stories in May

World models for proteins, robot hands in the wet lab, AI scientists in Nature, and safety filters that still cannot tell ordinary biology from risky biology.

Peter Ottsjö

Here's what we know about Biohub's world model for proteins

May 28, 2026

•

7 min read

Here's what we know about Biohub's world model for proteins

Plus: AI makes prime editing less fragile, Claude gets biosecurity-tested, and Insilico creates a longevity model.

Retro raises at $1.8B to move aging biology into the clinic

May 24, 2026

•

4 min read

Retro raises at $1.8B to move aging biology into the clinic

Plus: Incyte feeds Genesis its data, and AI designs RNA pseudoknots - without an AlphaFold moment.

Now it’s undeniable: AI scientists are here

May 21, 2026

•

9 min read

Now it’s undeniable: AI scientists are here

Plus: MouseMapper’s AI maps disease across the whole body, Hugging Face opens a faster DNA model, and Genentech gives virtual cells a tougher test.

“No virtual cell model actually uses AlphaFold”

May 16, 2026

•

9 min read

“No virtual cell model actually uses AlphaFold”

Plus: Morgan Levine on the wrong AI for aging, AI agents tie humans at protein design, and Isomorphic raises $2.1B.

Making sense of Isomorphic’s $2B raise

May 11, 2026

•

5 min read

Making sense of Isomorphic’s $2B raise

Plus: Young AI talent shuns pharma, DeepMind’s AlphaEvolve reaches genomics, and Kanvas maps the microbiome.

Physical AI is coming for the wet lab

May 7, 2026

•

7 min read

Physical AI is coming for the wet lab

Plus: ARPA-H’s AI research engine, digital twins for donor lungs, and OpenBind’s new drug-design dataset

DeepMind says the AI will see you now

May 4, 2026

•

6 min read

DeepMind says the AI will see you now

Plus: a world model that simulates drug and lifestyle interventions person by person, perturbation prediction clears the bar, and a physics lab trains one model on DNA, RNA, and protein.

The TOP10 AI x bio stories in April

May 2, 2026

•

3 min read

The TOP10 AI x bio stories in April

Billion-dollar deals, enzymes nature never made, and virtual patients built from 7.2 million real ones.

Here's the Human Genome Project for virtual cells

Apr 29, 2026

•

6 min read

Here's the Human Genome Project for virtual cells

Plus: Lilly’s $2.25B bet on AI-designed gene insertion, a literature agent that reads the pictures, and the FDA takes aim at the clinical trial bottleneck.